Accelerating the development of priority formulations in childhood cancer: target product profiles for paediatric formulations of cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, temozolomide

Overview

This document summarizes the proceedings and outcomes of a technical consultation designed to develop target product profiles for six priority childhood cancer medicines: cyclophosphamide, etoposide, mercaptopurine (6MP), methotrexate, procarbazine and temozolomide. The meeting was held from 9 to 13 December 2024 and was followed up with an additional consultation with the experts of the Target Product Profile Development Group on 19 June 2025.